Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

An Exploratory Study of Using Magnetic Resonance Prognostic Imaging Markers for Radiotherapy In Patients With Cervix Cancer (EMPIRIC Study) (EMPIRIC)

5. september 2022 opdateret af: East and North Hertfordshire NHS Trust

An Exploratory Study of Using Magnetic Resonance Prognostic Imaging Markers for Radiotherapy In Patients With Cervix Cancer

Patients with cervical cancer that has not spread to other parts of the body can be cured with radiotherapy. One of the reasons radiotherapy can fail is because there are areas within the tumour that have a poor oxygen supply which makes them resistant to radiotherapy. This study aims to assess if it is feasible using special types of magnetic resonance imaging (MRI) - multi-parametric (MP) MRI to identify areas of low oxygen within the tumour so a higher dose of radiation can be given specifically to these areas to overcome the resistance and potentially improve cure rates without increasing side effects.

Studieoversigt

Status

Rekruttering

Betingelser

Detaljeret beskrivelse

The study is an early exploratory study which will use MP MRI to predict which patients with locally advanced cervical cancer are likely to respond less well to chemoradiotherapy treatment, identify those patients and then intervene.

Hypoxia (deprivation of oxygen supply at tissue level) has long been shown to be a major cause of radiation resistance in various tumour sites and has been shown to be a harmful factor in cervical cancer and is associated with poor outcomes for patients. The aim of the study is to scan patients using different MP MRI sequences, each of which will measure different things, including blood flow, tumour necrosis and oxygen levels to determine hypoxia. This will be the first study to use the 3 different types of MRI scan (Diffusion Weighted - DWI, Dynamic Contrast Enhanced - DCE and Blood Oxygen Level Dependent - BOLD) at 3 different time points during the whole course of chemoradiotherapy.

The first scans will be prior to chemoradiotherapy treatment, the second set will be in week 2 and the final set in week 5. The imaging parameters from the MP MRI scans will be used as a surrogate markers of hypoxia. If high levels of hypoxia is identified using MP MRI, a prognostic imaging biomarker model can be developed to predict treatment outcomes of patients with locally advanced cervical cancer after chemoradiotherapy.

This study has potential to benefit all patients with locally advanced cervical cancer undergoing radical radiotherapy through the provision of more robust risk stratification. Improved risk stratification will result in more personalised treatment of better quality leading potentially to more cures and less side effects. As reported by Cancer Research UK, 3200 women are diagnosed with cervical cancer each year in the UK. 40% of these women are treated with radical radiotherapy, all of whom may benefit from the outputs of this study.

Undersøgelsestype

Observationel

Tilmelding (Forventet)

40

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

  • Det Forenede Kongerige
      • Northwood, Det Forenede Kongerige
        • Rekruttering
        • Mount Vernon Cancer Centre
        • Kontakt:
          • Yat Man Tsang
          • Telefonnummer: 02038262624
        • Ledende efterforsker:
          • Yat Man Tsang

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

N/A

Køn, der er berettiget til at studere

Kvinde

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Participants with locally advanced cervical cancer

Beskrivelse

Inclusion Criteria:

  • Histologically confirmed FIGO stage Ib2-IVa squamous, adeno or adenosquamous carcinoma of the cervix.
  • Clinically and/or radiographically documented measurable disease with at least one site of disease unidimensionally measurable as per RECIST 1.1
  • All detectable disease including pelvic/para-aortic nodes encompassable within radical high-dose radiation field
  • Deemed suitable and fit for radical chemoradiation
  • ECOG performance status 0 - 1
  • Aged 18 and over
  • Documented negative pregnancy test (if applicable)
  • Capable of providing written or witnessed informed consent according to ICH/GCP and national/local guidelines prior to registration

Exclusion Criteria:

  • Previous pelvic malignancy (regardless of interval since diagnosis)
  • Previous malignancy not affecting the pelvis (except basal cell carcinoma of the skin) where disease free interval is less than 10 years
  • Evidence of distant metastasis i.e. any non-nodal metastasis beyond the pelvis
  • Previous pelvic radiotherapy
  • Prior diagnosis of Crohn's disease or Ulcerative colitis
  • Uncontrolled cardiac disease (defined as cardiac function which would preclude hydration during cisplatin administration)
  • Previous record of allergic reaction to Gadolinium-based contrast media and any other contra-indication to magnetic resonance imaging (MRI)
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the study
  • Participation in any interventional trials

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
To determine if multi-parametric MRI (MP MRI) can be used to predict progression-free survival of patients with locally advanced cervical cancer after chemoradiotherapy.
Tidsramme: 1 and 2 years
Progression-free survival measured by number of patients with local, distant and nodal progression
1 and 2 years
To determine if multi-parametric MRI (MP MRI) can be used to predict overall survival of patients with locally advanced cervical cancer after chemoradiotherapy.
Tidsramme: 1 and 2 years
Overall survival measured by number of patients with overall survival
1 and 2 years

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Temporal changes in MP MR parameters during chemoradiotherapy and the identification of a prognostic imaging biomarkers.
Tidsramme: 2 years
Parameters measured: Extravascular extracellular space volume fraction Ve (%), Transfer constant Ktrans (min-1), Rate Constant kep (min-1), Blood volume fraction vp (%), Apparent diffusion coefficient ADC (um2/sec), BOLD-based reversible transverse relaxation rate R2* (sec-1), Relaxation times (sec-1), 2nd order Haralick textural radiomic features
2 years

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Molecular markers correlated with imaging parameters and evaluated independently and in combination with respect to prognostic impact.
Tidsramme: 2 years

Tissue samples will assess immunohistochemical markers of hypoxia:

(CA IX, GLUT-1), vascularity (VEGF) and epithelial mesenchymal transition(CD44, SOX-2).

Blood samples - Circulation Tumour Cells (CTCs) will be classified into three subpopulations with respect to metastatic potential using epithelial mesenchymal transition markers: epithelial CTCs (EpCAM or CK8), mesenchymal CTCs (vimentin or TWIST) and mixed phenotype CTCs (both markers). The CTC phenotype ratio at various timepoints will be correlated with imaging parameters and evaluated independently and in combination with respect to prognostic impact.
2 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

East and North Hertfordshire NHS Trust

Samarbejdspartnere

University of Manchester
Brunel University

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

5. august 2022

Primær færdiggørelse (Forventet)

1. marts 2026

Studieafslutning (Forventet)

1. marts 2026

Datoer for studieregistrering

Først indsendt

5. september 2022

Først indsendt, der opfyldte QC-kriterier

5. september 2022

Først opslået (Faktiske)

8. september 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

8. september 2022

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

5. september 2022

Sidst verificeret

1. september 2022

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • RD2021-29

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Livmoderhalskræft

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Kenya

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner